Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access

09/23/2021 | 07:01pm EDT

Sept 24 (Reuters) - A World Health Organization (WHO) panel on Friday recommended the use of Regeneron and Roche's COVID-19 antibody cocktail for patients at high risk of hospitalisations and those severely ill with no natural antibodies.

The treatment has been granted U.S. emergency use authorisation, having gained attention when used to treat former President Donald Trump's COVID-19 illness last year. Europe is reviewing the therapy, while Britain approved it last month.

While acknowledging costs associated with the treatment, the WHO panel said that given the recorded benefits of the therapy, "the recommendations should provide a stimulus to engage all possible mechanisms to improve global access to the intervention and associated testing."

In a separate statement, the WHO called on Regeneron to lower prices and distribute the treatment equitably worldwide, especially in low- and middle-income countries. The agency also urged the firms to transfer tech to help make biosimilars.

The treatment, called Ronapreve, or REGEN-COV in the United States, has been a big earner for Regeneron, logging in U.S. sales of $2.59 billion in the second quarter.

Regeneron is going to supply 1.4 million additional doses of REGEN-COV https://www.reuters.com/world/us/us-buy-14-mln-additional-doses-regenerons-covid-19-therapy-2021-09-14 to the U.S. government by Jan. 31 at a cost of $2,100 per dose.

French medical charity Medecins Sans Frontieres (MSF) echoed the UN agency's comments, demanding that affordable and sustainable access to life-saving drugs during the pandemic must be ensured.

The WHO guidelines, published in the British Medical Journal (BMJ), were based on data from a large British study and three other trials that have not yet been peer reviewed.

In June, Britain's RECOVERY trial https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-covid-19-therapy-cuts-deaths-among-hospitalised-patients-who-lack-2021-06-16 found the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.

The treatment, a combination of casirivimab and imdevimab, is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS 0.53% 572.36 Delayed Quote.18.47%
ROCHE HOLDING AG -0.56% 355.8 Delayed Quote.15.15%
All news about REGENERON PHARMACEUTICALS
10/22SANOFI : Regeneron's Dupixent Meets Primary, Key Secondary Endpoints in Phase 3 Trial in P..
MT
10/22REGENERON, SANOFI : Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
DJ
10/22SANOFI : Regeneron's Dupixent Cuts Itch in Late-Stage Skin Disease Study
MT
10/21REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
10/20SANOFI : Regeneron Win Expanded US FDA Nod for Asthma Drug Dupixent
MT
10/20REGENERON PHARMACEUTICALS : Sanofi Say FDA Has Expanded Approval of Dupixent to Include Ch..
MT
10/20REGENERON PHARMACEUTICALS : FDA Expands Approval of Dupixent® (dupilumab) to Include Child..
PR
10/14REGENERON PHARMACEUTICALS : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Tr..
MT
10/14Health Care Stocks Climb Pre-Bell Thursday
MT
10/14REGENERON PHARMACEUTICALS : US FDA Accepts Regeneron's Regen-Cov For Priority Review for C..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 14 402 M - -
Net income 2021 7 227 M - -
Net Debt 2021 - - -
P/E ratio 2021 8,65x
Yield 2021 -
Capitalization 59 507 M 59 507 M -
Capi. / Sales 2021 4,13x
Capi. / Sales 2022 4,88x
Nbr of Employees 9 635
Free-Float 82,0%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 572,36 $
Average target price 681,64 $
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS18.47%59 507
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
VERTEX PHARMACEUTICALS-22.35%47 610
BEIGENE, LTD.46.63%35 360